BACKGROUND: @entity260 is a common @entity4934 after major surgeries. There is no conclusive approach for prevention of @entity933 in these @entity1 . OBJECTIVE: In this study, efficacy of @entity7782 for prevention of @entity260 was evaluated. METHODS: @entity933 status of surgical @entity1 was evaluated postoperatively at the time of admission to the intensive care unit (ICU) using the Confusion Assessment Method (CAM-ICU) scale. @entity1 without @entity933 were assigned to the @entity7782 or placebo group based on the simple randomization method. @entity1 received @entity7782 or placebo tablet at a dose of 4 mg 3 times per day for 7 days. @entity1 were monitored daily for incidence of @entity933 . RESULTS: Changes in the incidence rates of @entity933 over time during the study phase (P = 0.04) and between the groups showed statistically significant differences (P = 0.029). However, severity of @entity933 was not significantly different between the @entity7782 and placebo groups during the study period. CONCLUSION: It seems that @entity7782 with its diverse effects can be a potential option for prevention of @entity260 . In this pilot study, @entity7782 significantly decreased the incidence but not severity of @entity260 .

XXXX for the Prevention of @entity260 : A Pilot Study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity7782 :: ('MESH:D003533', 'Chemical') :: ['cyproheptadine'] @entity4934 :: ('MESH:D019954', 'Disease') :: ['neurobehavioral complication'] @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative delirium', 'Postoperative delirium'] @entity933 :: ('MESH:D003693', 'Disease') :: ['delirium', 'Delirium']
@entity7782 :: (MESH:D003533,Chemical) :: ['Cyproheptadine']
